Form 4: Sana Biotechnology Director Receives Stock Option Grant
Director Equity Grant
Director Richard Mulligan was granted 90,000 stock options in Sana Biotechnology, Inc. as part of a standard equity incentive.
Summary
- Director Richard Mulligan received a grant of 90,000 stock options for Sana Biotechnology, Inc. (SANA) common stock.
- The options have an exercise price of $2.96 per share.
- The grant date for the transaction was June 4, 2026.
- The options are scheduled to vest in full on the earlier of June 4, 2027, or immediately prior to the 2027 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standardized vesting schedule ensures continued service commitment from the director.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $2.96 exercise price.
- Dependence on the director's continued service to satisfy vesting requirements.
Future Outlook
The options vest in one year, contingent upon the director's continued service to the company.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of board members.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard corporate governance practices for mid-cap biotechnology firms.
- The grant size is typical for non-employee director compensation packages in the life sciences industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of attorneys-in-fact to handle SEC filings for Richard Mulligan. | 2025-10-20 | Administrative update to ensure timely regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 4, 2027.
- Potential exercise of options by the director after the vesting date.
Key Dates
| Date | Description |
|---|---|
| 2025-10-20 | Date of Power of Attorney execution. |
| 2026-06-04 | Date of the stock option grant transaction. |
| 2026-06-05 | Date of filing the Form 4 with the SEC. |
| 2027-06-04 | Vesting date for the stock options. |
| 2036-06-03 | Expiration date for the stock options. |
Keywords
Sana Biotechnology, SANA, Stock Options, Director Compensation, Equity Incentive, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.